FDG-PET SCAN: A NEW PARADIGM FOR FOLLICULAR LYMPHOMA MANAGEMENT.
Authors:
Open Access
- 26 December 2016
- journal article
- review article
- Published by Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy in Mediterranean Journal of Hematology and Infectious Diseases
- Vol. 9 (1) , e2017029
Abstract
In the present review the reader will be led across the most relevant observations that prompted oncologists and haematologist to consider FDG-PET/CT as a new paradigm for FL management in clinical practice. The contribute of functional imaging for lymphoma staging, restaging, prognostication, and tumour burden definition before radio-chemo-immunotherapy will be reviewed in detail. Moreover, a special focus will be addressed to technical and practical aspects of PET scan reporting, which have been set during the last decade in order to ensure the reproducibility of the therapeutic results. Finally, the predictive role of PET/CT on long-term treatment outcome will be compared with other well-known prognosticator as minimal residual disease (MRD) detection by gene rearrangement assessment by molecular biology.Keywords
This publication has 57 references indexed in Scilit:
- 90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent TrialJournal of Clinical Oncology, 2013
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic PerspectivesJournal of Clinical Oncology, 2013
- Strategies to Increase Drug Penetration in Solid TumorsFrontiers in Oncology, 2013
- Impact of [18F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High–Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMSJournal of Clinical Oncology, 2012
- Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using 89Zr-ibritumomab tiuxetan and PETEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- Factors determining antibody distribution in tumorsTrends in Pharmacological Sciences, 2008
- Risk and Clinical Implications of Transformation of Follicular Lymphoma to Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- 131I-Tositumomab Therapy as Initial Treatment for Follicular LymphomaNew England Journal of Medicine, 2005
- Treatment of low‐grade non‐Hodgkin's lymphomas: Assessment of doxorubicin in a controlled trialHematological Oncology, 1990